Centiva Capital LP bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 7,551 shares of the company's stock, valued at approximately $588,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock valued at $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. bought a new position in AstraZeneca in the 2nd quarter valued at $26,000. Capital Performance Advisors LLP purchased a new stake in AstraZeneca in the third quarter worth $28,000. Hobbs Group Advisors LLC purchased a new stake in AstraZeneca in the second quarter worth $35,000. Finally, CarsonAllaria Wealth Management Ltd. boosted its stake in shares of AstraZeneca by 168.0% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 536 shares of the company's stock valued at $42,000 after purchasing an additional 336 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Stock Up 1.0 %
NASDAQ:AZN traded up $0.67 during trading hours on Friday, reaching $68.20. The company's stock had a trading volume of 6,813,708 shares, compared to its average volume of 6,463,041. The stock has a 50 day moving average price of $71.27 and a two-hundred day moving average price of $77.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a market capitalization of $211.46 billion, a P/E ratio of 32.63, a price-to-earnings-growth ratio of 1.25 and a beta of 0.45. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the company posted $0.87 EPS. The business's revenue for the quarter was up 18.0% compared to the same quarter last year. Equities analysts predict that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently commented on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Finally, TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Monday, August 12th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $89.75.
Check Out Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
